Year: 2023

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA, JAPAN, AUSTRALIA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange announcement by Prosafe SE (the “Company” or “Prosafe”) on 29 November 2023 announcing the submission of a prospectus dated 29 November 2023 (the “Prospectus”) and the subsequent offering (the “Subsequent Offering”) of up to 1 333 333 new shares (the “Offer Shares”) in the Company, at a subscription price of NOK 60 per share. The subscription period in the Subsequent Offering commences today, on 4 December 2023 at 09:00 hours (CET), and ends on 15 December 2023 at 16:30 hours (CET). The Subsequent...

Novel ultra-high affinity ligand OncoFAP targets Fibroblast Activation Protein (FAP), associated with a variety of solid tumors Licensing agreement between Philochem and Blue Earth Diagnostics, one of the Bracco family of companies, encompasses applications of OncoFAP for diagnostic and medical imaging Philogen’s Phase I clinical trial with investigational 68Ga-OncoFAP is underway in Europe, with first three patients successfully imaged Blue Earth Diagnostics will assume further clinical development and future commercialization activities of OncoFAP for diagnostic or medical imaging purposes worldwideZURICH, Switzerland and OXFORD, United Kingdom and MONROE TOWNSHIP, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) — Philochem AG, a wholly owned subsidiary of Philogen S.p.A., and Blue Earth Diagnostics, a Bracco company and recognized...

BRISBANE, Australia, Dec. 04, 2023 (GLOBE NEWSWIRE) — NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX” or the “Company”), a leading battery materials and technology company, today announced that members of the executive team are scheduled to participate in the following upcoming investor events in December 2023:Janney Montgomery Scott Clean Energy Investment Symposium to be held December 5th-6th in New Orleans, LA; Chardan’s Battery Technology Virtual Conference Series to be broadcast Monday, December 11th; and Bank of America Battery Tech Mini-Conference with NOVONIX presenting virtually on Tuesday, December 12th at 11:45 am ESTNOVONIX management will be available to host one-on-one and group investor meetings during the conferences. Presentation materials and available webcast links will be available prior to each event...

Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases both as standalone medicines and in combination with Roche’s in-house assets Lead asset CT-388 is a Phase-2 ready dual GLP-1/GIP agonist with best-in-class potential for the treatment of obesity and its comorbidities Under the terms of the agreement, Roche will pay a purchase price of USD 2.7 billion upfront and additional milestone payments of up to USD 400 millionBasel, 4 December 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc. (“Carmot”), a privately owned US company based in Berkeley, California. Carmot’s R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class...

Commercial Court hearing to examine the takeover offer scheduled for December 18, 2023 Paris, France, December 4, 2023 – 7:00 am (CET) – Pixium Vision SA (Euronext Growth Paris – FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, announces that the Paris Commercial Court will hold a hearing to examine the takeover offer received by the court-appointed administrators and to decide on the outcome of the Company’s reorganization proceedings on December 18, 2023. As a reminder, only one takeover offer was submitted before the deadline for submission of offers, which was set to November 20, 2023 at noon. The candidate will have until December 13, 2023 to improve its offer. Concurrently with the decision of the Commercial...

          Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in ChinaMithra signs binding Head of Terms for a twenty-year partnership with Gedeon-Richter for the development and commercialization of ESTELLE ® and DONESTA® in ChinaMithra to receive EUR 4.5 million in combined milestone payments at signature of the license agreements with additional combined regulatory milestones of EUR 1.2 millionMithra eligible to receive a combined total of EUR 8.5 million sales related milestones and additional high-single-digit to low-double-digit percent tiered royalties after launchESTELLE® to target an addressable contraceptive market in China valued at EUR 104 million annually (with a 5-year CAGR ~15%)1DONESTA® to target an addressable menopause market in China valued at EUR 87 million annually...

Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®Primary endpoint met with 97% seroresponse rate 24 months after a single vaccination Antibody levels remained high and well above the seroresponse threshold, further supporting the anticipated long-term durability of the immune response No safety concerns identified in long-term follow upSaint-Herblain (France), December 4, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive antibody persistence data twenty-four months after vaccination with a single dose of its chikungunya vaccine IXCHIQ®, further supporting the anticipated long-term durability of the immune response and in line with positive twelve-month persistence data the Company reported in December 20221. These...

SHENZHEN, China, Dec. 04, 2023 (GLOBE NEWSWIRE) — LexinFintech Holdings Ltd. (“Lexin” or the “Company”) (NASDAQ: LX), a leading technology-empowered personal financial service enabler in China, today announced that its board of directors has appointed Mr. Zhanwen Qiao as the Company’s Chief Risk Officer, effective on 4th Dec, 2023. Mr. Zhanwen Qiao has over a decade of experience as a senior leader in risk management space at a top-tier consumer finance company in China. Prior to joining Lexin, Mr. Qiao served as a senior director at Ant Group and deputy general manager of Chongqing Ant Consumer Finance, where he joined in April 2012, responsible for risk management for Chongqing Ant Consumer Finance. Mr. Qiao has deeply involved in the entire process of building and iterating Ant Group’s consumer credit risk management system,...